Beyond the genome with multiomics: Unlocking deeper biology

Illumina is going beyond the sequencer, developing transformative technologies that empower researchers to explore biology with unprecedented depth and dimension.

In this session, we unveil breakthrough innovations that accelerate insights across genomics, proteomics, single-cell, and spatial biology:

• Illumina Protein Prep delivers unmatched discovery power, exceptional reproducibility, and the lowest cost per protein target. Powered by NGS, it quantifies human proteins across 200+ biological pathways, bringing proteomics to the forefront of multiomic research.
• Illumina Single Cell 3' RNA Prep, the first Illumina scRNA-seq kit, is designed to scale to million cell reactions. In addition to enabling huge single cell transcriptomics studies, this unlocks our upcoming CRISPR kit to enable high-powered perturb seq studies made practical by the unmatched throughput of NovaSeq X and the speed of DRAGEN analysis.
• Illumina Spatial Technology leverages our deep expertise in flow cell innovation to deliver higher sensitivity and resolution for mapping complex tissues and understand cellular behavior at an unprecedented scale. This end-to-end solution integrates seamlessly with Illumina sequencers, offering clarity without compromise.
• Illumina 5-Base Solution introduces a fundamentally different approach to DNA methylation analysis. With novel chemistry and optimized algorithms, it enables simultaneous genomic and epigenomic discoveries in a single readout - streamlining workflows and expanding insight.
• Illumina Connected Multiomics will support true multiomics integration - combining genomic, epigenomic, proteomic, spatial, and single-cell data in one unified environment.

This is more than innovation—it’s the future of multiomics. And it’s happening now.

Speakers

Fiona Kaper, PhD
VP, Head of Assay R&D
Illumina

Brendan Keating, PhD
Assoc Prof, Div of Transplantation, Dept of Surgery, and Institute of Systems Genetics
NYU Langone Health

Matthew Brown, PhD
Chief Scientific Officer, Genomics England
Professor of Medicine, King’s College London

Sheila Dodge, MLA, MBA
Chief Operating Officer, Broad Clinical Labs
Sr Dir, Strategic Financial Operations, Platforms; Institute Scientist, The Broad